Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of type 2 diabetes mellitus.~2. Male and female patients on diet and exercise regimen, pre-treated with immediate release metformin for at least 12 weeks, and patients should be on a dose higher or equal to 1500 mg/day of metformin, or maximum tolerated dose, or maximum dose as per local label.~3. HbA1c higher or equal to 8.0% and lower or equal to 10.5% at screening visit.~4. Age 18 years or more at screening.~5. Body Mass Index lower or equal to 45 kg/m2 at screening visit.~6. Signed and dated written informed consent.~Exclusion criteria:~1. Uncontrolled hyperglycemia with glucose level above 270 mg/dl (above 15 mmol/dl) after an overnight fast.~2. Use of any other antidiabetic drug (except metformin background therapy).~3. Acute coronary syndrome, stroke or TIA within 3 months prior to informed consent.~4. Indication of liver disease.~5. Impaired renal function.~6. Gastrointestinal surgery.~7. Treatment with anti-obesity drugs within 3 months prior to screening, or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight.~8. Current treatment with systemic steroids at time of informed consent or uncontrolled endocrine disorder except type 2 diabetes mellitus.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Linagliptin (Type: ACTIVE_COMPARATOR): 5 mg once daily
- Empagliflozin + Linagliptin low dose (Type: EXPERIMENTAL): 1 tablet once daily
- Empagliflozin + Linagliptin high dose (Type: EXPERIMENTAL): 1 tablet once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).